肺癌类器官模型中药与西药单药及联合用药敏感性分析
该研究构建了10例肺腺癌患者来源的类器官模型,成功培养7例,其中3例复苏成功用于药敏分析。研究发现不同来源类器官对同一药物反应不同,奥希替尼在EGFR突变模型中活性最强,中药活性成分单用无显著抑制效应,中西药联合用药在各模型中均显示更强抑制效果。
要点
- 患者来源肺癌类器官可反映个体间药物敏感性差异。
- EGFR突变模型中奥希替尼活性强且与临床疗效吻合。
- 中药活性成分单用无显著抑制,联合用药增强抑制效果。
核心结论
- 患者来源肺癌类器官模型能够反映个体间药物敏感性差异,为体外快速筛选敏感方案及中西药联合用药等个性化治疗策略提供可行路径。
研究设计与样本
- 收集天津市第五中心医院2024年6月至2025年6月病理诊断明确的肺腺癌样本10例(手术肿瘤组织6例,胸腔积液4例)进行体外培养构建类器官模型。
- 采用形态学观察、HE染色及免疫组化验证类器官与亲本组织一致性。
- 在成功构建的类器官模型中应用抗肿瘤单药、中药活性成分及中西药联合方案进行药敏测试,计算IC50和标准化AUC评估敏感性。
主要发现
- 10例样本中成功培养类器官7例,类器官与亲本组织形态学与分子标志物表达相似。
- 7例类器官冻存复苏后成功复苏3例,不同来源类器官对同一药物反应不同。
- 1例具有EGFR基因拷贝数增加及EGFR p.E746_A750del突变的模型中,奥希替尼IC50=1.91 μmol/L,显著优于其他测试药物,结果与临床疗效吻合。
- 中药活性成分单用未见显著抑制效应,标准化AUC值均>0.925。
- 联合用药在所有类器官模型中均表现出更强抑制效果,IC50值较单药有不同程度降低。
关键数值与推荐
- 样本1和3顺铂单药IC50分别为152.70、475.00 μmol/L,联合用药后降至127.30、121.50 μmol/L。
- 各模型中抗肿瘤药物单药IC50最低的5-氟尿嘧啶为28.08 μmol/L,联合用药后进一步降至11.26 μmol/L。
- 奥希替尼在EGFR突变模型中IC50=1.91 μmol/L,显著优于紫杉醇、顺铂、GP方案和PP方案。
临床怎么用
- 可利用患者来源肺癌类器官模型进行体外快速药敏筛选,辅助个体化治疗方案选择。
- 对于EGFR突变患者,类器官药敏结果与奥希替尼临床疗效一致,支持其用于预测靶向药物敏感性。
- 中西药联合用药在类器官中显示增强抑制效果,但中药活性成分单用无显著抑制,联合方案需进一步验证。
局限性
- 样本量较小(10例),成功复苏用于药敏分析的模型仅3例。
- 仅1例模型具有基因组检测数据并与临床疗效比对。
- 研究为体外实验,结论需更大样本和体内研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To construct patient-derived lung cancer organoid models and evaluate the sensitivity of the organoids to antitumor monotherapies, active components of traditional Chinese medicine (TCM) and combined regimens of Chinese and Western drugs. Methods: A total of 10 pathologically confirmed lung adenocarcinoma specimens were collected from Tianjin Fifth Central Hospital between June 2024 and June 2025, including six surgical tumor tissue specimens and four pleural effusion samples. These samples were cultured in vitro to establish lung cancer organoid models. Morphological examination, hematoxylin and eosin (HE) staining, and immunohistochemical staining were used to verify the consistence between the organoids and their parental tissues. One organoid model with available genomic profiling data (n=1) was subjected to drug sensitivity testing against commonly used antitumor drugs/regimens, and the results were compared with the clinical response. In successfully established organoid models, antitumor monotherapies (5-fluorouracil [5-FU], cisplatin and osimertinib), active components of Chinese drugs (elemene and ginsenoside Rg3) and combined regimens of Chinese and Western drugs (cisplatin plus ginsenoside Rg3 and 5-FU plus ginsenoside Rg3) were applied. Cell viability was assessed, and the half-maximal inhibitory concentration (IC50) and normalized area under the curve (AUC) values were calculated for each treatment to evaluate drug sensitivity. Results: Among the 10 samples, organoids were successfully cultured from 7 samples, and the organoids closely resembled their parental tissues in morphology and molecular marker expression. In one organoid model with increased epidermal growth factor receptor (EGFR) gene copy number gain and the EGFR p.E746_A750del mutation, sensitivity testing of commonly used antitumor drugs/regimens, including osimertinib, paclitaxel, cisplatin, the GP regimen (gemcitabine plus cisplatin), and the PP regimen (pemetrexed plus cisplatin), showed that osimertinib exhibited potent antitumor activity (IC50=1.91 μmol/L), markedly superior to the other tested drugs, and the results were consistent with the clinical response. After cryopreservation and rivival, the 7 organoid lines were continued cultured and passaged; 3 were successfully recovered. Drug sensitivity analysis of the 3 successfully established lung cancer organoid models revealed that organoids from different sources responded differently to the same drug. Osimertinib and 5-FU showed higher activity in sample 1 and sample 2, respectively, whereas sample 3 was highly resistant to cisplatin. Active components of Chinese drugs used alone showed no significant inhibitory effect, with normalized AUC values all >0.925. Combination treatment showed stronger inhibition effect in all organoid models, and IC50 values decreased to varying degrees compared with monotherapy. In samples 1 and 3, the IC50 values of cisplatin monotherapy were 152.70 and 475.00 μmol/L, respectively, and decreased to 127.30 and 121.50 μmol/L after combination treatment. Among all models, 5-FU had the lowest monotherapy IC50 among the antitumor drugs (28.08 μmol/L), which was further reduced to 11.26 μmol/L after combination treatment. Conclusion: Patient-derived lung cancer organoid models capture interindividual differences in drug sensitivity and provide a feasible approach for rapid in vitro screening of sensitive regimens and for personalized therapeutic strategies, such as combined therapy with Chinese and Western drugs. 目的: 构建患者来源的肺癌类器官模型,评估类器官对抗肿瘤药物单药、中药活性成分及中西药联合用药方案的敏感性。 方法: 收集天津市第五中心医院2024年6月至2025年6月病理诊断明确的肺腺癌样本10例(手术肿瘤组织样本6例,胸腔积液样本4例),进行体外培养并构建肺癌类器官模型。采用形态学观察、HE染色及免疫组织化学染色验证类器官与亲本组织的一致性。选择具有基因检测信息的类器官模型(n=1),对常用抗肿瘤药物/方案进行药物敏感性测试,并与临床疗效比对。在成功构建的类器官模型中,应用抗肿瘤单药(5-氟尿嘧啶、顺铂、奥希替尼)、中药活性成分(榄香烯、人参皂苷Rg3)以及中西药联合用药方案(顺铂+人参皂苷Rg3、5-氟尿嘧啶+人参皂苷Rg3),检测细胞活力,计算各药物半数抑制浓度(IC50)和标准化曲线下面积(AUC),以评估药物敏感性。 结果: 10例样本中,成功培养类器官7例,类器官与亲本组织形态学与分子标志物表达相似。在1例具有表皮生长因子(EGFR)基因拷贝数增加及EGFR p.E746_A750del突变的类器官模型中,对常用抗肿瘤药物/方案[奥希替尼、紫杉醇、顺铂、GP方案(吉西他滨+顺铂)、PP方案(培美曲塞+顺铂)]进行敏感性测试,发现奥希替尼表现出极强的抗肿瘤活性(IC50=1.91 μmol/L),显著优于其他测试药物,结果与临床疗效吻合。7例类器官经过冻存、复苏后继续培养、传代,成功复苏3例。在成功复苏的3例肺癌类器官模型中进行药物敏感性分析,结果显示,不同来源类器官对同一药物的反应不同,奥希替尼、5-氟尿嘧啶分别在样本1和样本2中显示出较高活性,而样本3对顺铂高度耐药。中药活性成分单用未见显著抑制效应,标准化AUC值均>0.925。联合用药在所有类器官模型中均表现出更强的抑制效果,与单药相比IC50值均有不同程度的降低。样本1和3顺铂单药IC50值分别为152.70、475.00 μmol/L,联合用药后IC50降至127.30、121.50 μmol/L;各模型中抗肿瘤药物单药IC50值最低的5-氟尿嘧啶(28.08 μmol/L),联合用药后IC50也进一步降至11.26 μmol/L。 结论: 患者来源的肺癌类器官模型能够反映个体间的药物敏感性差异,为体外快速筛选敏感方案、中西药联合用药等个性化治疗策略提供了可行路径。.
引用
- Liu M, Zheng J, Li YX, et al. [Drug sensitivity analysis of monotherapy and combination therapy with Chinese and Western drugs in lung cancer organoid models]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42927948. doi:10.3760/cma.j.cn112152-20251219-00624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。